7 articles
2026-06-299 min readGLP-1 & weight loss
Lilly reported positive TRIUMPH-1 phase 3 retatrutide topline results, but retatrutide remains investigational. Learn how to read the 80-week data, safety caveats, FDA status, and online seller red flags.
2026-06-279 min readGLP-1 & weight loss
Retatrutide phase 2 results drew attention, but the medication remains investigational. Learn how to read the 24- and 48-week weight-loss data, safety signals, phase 3 status, and online seller red flags.
2026-05-168 min readGLP-1 & weight loss
FDA shortage status changed the GLP-1 compounding landscape. Here is how patients can ask safer questions about prescriptions, pharmacy sourcing, dosing, and alternatives without assuming every compounded option is available.
2026-05-169 min readGLP-1 & weight loss
GLP-1 microdosing is trending, but low dose does not mean low risk. Learn what evidence exists, what is still uncertain, and which safety questions to ask before changing a prescription plan.
2026-05-1610 min readGLP-1 & weight loss
Retatrutide is an investigational triple-hormone receptor agonist, not an FDA-approved weight-loss medication. Learn what trial results mean, why online offers deserve caution, and which approved options to discuss with a clinician now.
2026-05-169 min readGLP-1 & weight loss
Stopping a GLP-1 medication can lead to appetite return, weight regain, and loss of some cardiometabolic improvements for many people. Learn what to discuss with a clinician before tapering, pausing, or stopping semaglutide, tirzepatide, Wegovy, Ozempic, Zepbound, or Mounjaro.
2026-04-016 min readGLP-1 & weight loss
Compounded semaglutide and tirzepatide use the same active ingredients as Ozempic, Wegovy, Mounjaro, and Zepbound — prepared by US 503A/503B pharmacies. Here's what that actually means.